People ages 65 and up will likely reap significant out-of-pocket savings on prescription drugs when the negotiated prices take effect. But other benefits could pay bigger dividends in the long run.
Academic rigor, journalistic flair
Articles on Drugmakers
Displaying all articles
Drug development takes a great deal of time, money and effort. While future profits play a big factor in which diseases gets prioritized, advocacy and research incentives can also tilt the scale.
The shortages, which have been going on for years, have typically affected only low-cost generics rather than profitable brand-name drugs.
Moderna claims its scientists alone invented the mRNA sequence used to produce its COVID-19 vaccine. The US government, which helped fund the drug, disagrees.
New payment models may mean more of the people who need these treatments can get them.
Each dose of Pfizer has a long and complex path involving mixing, storage at temperatures colder than the South Pole and specific protocols that must be followed before it becomes a jab.
Health Canada devotes far more resources to getting new drugs onto the market compared to making sure that drugs already being sold are safe.
A tragic error showed how complicated it can be to distribute vaccines on a mass scale.
Our best shot at ending the pandemic is by achieving herd immunity through widespread use of a vaccine. But that won’t happen unless people believe it’s safe.
Top contributors
-
Postdoctoral Fellow in Precision Medicine and Emerging Biotechnologies, Arizona State University
-
Distinguished Professor of Pharmacy Practice, University of Connecticut
-
Senior Lecturer, Film and Media Studies, University of Pittsburgh
-
Professor of Law, Villanova University
-
Professor of Law and Public Health, The Ohio State University
-
Director of Health Policy, USC Schaeffer Center, and Associate Professor, University of Southern California
-
Dean Emeritus and Distinguished Service Professor Emeritus of Pharmacy, University of Pittsburgh
-
Professor of Technology and Operations, University of Michigan
-
Joel Lexchin is a Friend of The Conversation.
Professor Emeritus of Health Policy and Management, York University, Canada
-
Associate Professor of Public Health, Texas A&M University
